Norvir Generics Are Years Away, Even If NIH Exercises “March-In” Rights
Executive Summary
Generic versions of Abbott's protease inhibitor Norvir (ritonavir) would still face patent litigation, even if the National Institutes of Health decides to "march in" on the patents for the drug